Luda Diatchenko | |
---|---|
Born | Moscow, Russia |
Occupation(s) | Professor, McGill University |
Known for | Identifying “pain genes” and biological pathways contributing to human pain |
Awards | Fellow of the Royal Society of Canada |
Academic background | |
Education | MD and MS, Russian State Medical University, PhD (Molecular Biology), Russian State Medical University; National Cardiology Research Center |
Academic work | |
Discipline | Molecular Genetics |
Sub-discipline | Human Pain Genetics |
Institutions | Alan Edwards Centre for Research on Pain,McGill University,McGill University Faculty of Medicine,McGill University Faculty of Dentistry |
Notable ideas | Genetic variants of COMT associated with pain sensitivity and the risk of chronic pain conditions;protective role of neutrophil-driven inflammation for pain resolution;individual differences in responses to analgesic drugs driven by genetics |
Website | Human Pain Genetics Lab |
Luda Diatchenko is an academic and researcher at McGill University in Quebec,Canada,with a research focus on pain in humans. [1] She is the Canada Excellence Research Chair (CERC) in Human Pain Genetics Laureate [2] and the Fellow of the Royal Society of Canada. [3]
Diatchenko grew up and completed her studies in Moscow,Russia. She completed her MD and Master of Science (Biochemistry) in 1990 from the Russian State Medical University (now known as the Pirogov Russian National Research Medical University). She continued her studies here and at the National Cardiology Research Center,and was awarded a PhD in Molecular Biology in 1993.
Diatchenko began her career in industry with 7 years in research and development at CLONTECH Laboratories (now Takara Bio USA) in Palo Alto,California. In 2000,her career in academia began as a Visiting Research Assistant Professor at the Center for Neurosensory Disorders at the University of North Carolina,Chapel Hill. She has continued since then to have roles in both academia and industry. Between 2000 –2013,she led her research group at the University of North Carolina,becoming a Full Professor in 2013. Since 2013,she has led a research group at McGill University,in Montreal,Canada,in the Alan Edwards Centre for Research on Pain in the Faculty of Dentistry and Medicine. Her recruitment to McGill University included a Canada Excellence Research Chair (CERC), [4] which facilitated her work in creating a Human Pain Genetics Program at McGill. She continues to be involved in industry research through advisory board membership or as a consultant.
Diatchenko pioneered the field of human pain genetics,where she has substantively contributed to the current body of knowledge through her work. Her work has covered genetics and pharmaceutics. Diatchenko has been instrumental in identifying new pain drug targets through a reverse genetic approach that starts with human genetics and genomics,which has led to discovering pain genes and biological pathways that contribute to human pain. Her research program revealed a genetic variation in the human catechol-O-methyltransferase gene with pain sensitivity and the risk of chronic pain conditions (Hum. Mol. Genet.,2004;Science,2006),individual differences in responses to analgesic drugs being driven by genetics (Hum. Mol. Genet.,2009;Pain,2020),and the protective role of neutrophil-driven inflammation for pain resolution in patients with acute lower back pain,where inhibiting inflammation leads to short-term analgesia but long-term pain states (Sci.Transt.Med.,2022). [5] [6] [7]
Diatchenko also believes in and contributes to open science to advance our understanding of the molecular mechanisms of pain. Her lab's Human Pain Genetics Database (HPGdb) summarizes all extant data on the genetic contributors of pain and the Transcriptomics Pain Signatures Database (PSGS) summarizes all available data on genome-wide transcriptomics in human pain conditions and experimental pain models. Diatchenko has also been prolific in developing molecular genetic methodologies. She pioneered Suppression Subtractive Hybridization (SSH) nearly 30 years ago,which is still widely used and highly cited times (:Proc. Natl. Acad. Sci.,U.S.A.,1996). She and colleagues have also developed a SMART technology (Biochem Biophys Res Commun.,1997),and Factorial reporter system that measures the activities of multiple transcription factors in a living cell. (Nat Methods,2008)
Diatchenko has been an active member of several professional societies,such as the International Association for the Study of Pain (IASP),playing various roles in multiple committees. At IASP,in 2012,she founded and was Elected Chair of the Special Interest Group (SIG) in Genetics and Pain. She also consults for policy-making agencies such as the National Institutes of Health,the US National Academy of Sciences and the US Surgeon General of the United States.
Migraine is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity. Other characterizing symptoms may include vomiting, cognitive dysfunction, allodynia, and dizziness. Exacerbation of headache symptoms during physical activity is another distinguishing feature. Up to one-third of migraine sufferers experience aura, a premonitory period of sensory disturbance widely accepted to be caused by cortical spreading depression at the onset of a migraine attack. Although primarily considered to be a headache disorder, migraine is highly heterogenous in its clinical presentation and is better thought of as a spectrum disease rather than a distinct clinical entity. Disease burden can range from episodic discrete attacks to chronic disease.
Ehlers–Danlos syndromes (EDS) are a group of 13 genetic connective-tissue disorders. Symptoms often include loose joints, joint pain, stretchy velvety skin, and abnormal scar formation. These may be noticed at birth or in early childhood. Complications may include aortic dissection, joint dislocations, scoliosis, chronic pain, or early osteoarthritis. The current classification was last updated in 2017, when a number of rarer forms of EDS were added.
C57BL/6, often referred to as "C57 black 6", "B6", "C57" or "black 6", is a common inbred strain of laboratory mouse.
Opioid-induced hyperalgesia (OIH) or opioid-induced abnormal pain sensitivity, also called paradoxical hyperalgesia, is an uncommon condition of generalized pain caused by the long-term use of high dosages of opioids such as morphine, oxycodone, and methadone. OIH is not necessarily confined to the original affected site. This means that if the person was originally taking opioids due to lower back pain, when OIH appears, the person may experience pain in the entire body, instead of just in the lower back. Over time, individuals taking opioids can also develop an increasing sensitivity to noxious stimuli, even evolving a painful response to previously non-noxious stimuli (allodynia). This means that if the person originally felt pain from twisting or from sitting too long, the person might now additionally experience pain from a light touch or from raindrops falling on the skin.
25-Hydroxyvitamin D 1-alpha-hydroxylase also known as calcidiol 1-monooxygenase or cytochrome p450 27B1 (CYP27B1) or simply 1-alpha-hydroxylase is a cytochrome P450 enzyme that in humans is encoded by the CYP27B1 gene.
ATP-binding cassette sub-family C member 4 (ABCC4), also known as the multidrug resistance-associated protein 4 (MRP4) or multi-specific organic anion transporter B (MOAT-B), is a protein that in humans is encoded by the ABCC4 gene.
Homeobox protein Hox-A1 is a protein that in humans is encoded by the HOXA1 gene.
Mucin-7 is a protein that in humans is encoded by the MUC7 gene. In animals, the MUC7 gene is found in most placental mammals, but not marsupials.
The tail flick test is a test of the pain response in animals, similar to the hot plate test. It is used in basic pain research and to measure the effectiveness of analgesics, by observing the reaction to heat. It was first described by D'Amour and Smith in 1941.
Thioredoxin domain-containing protein 3 (TXNDC3), also known as spermatid-specific thioredoxin-2 (Sptrx-2), is a protein that in humans is encoded by the NME8 gene on chromosome 7.
The melanocortin 1 receptor (MC1R), also known as melanocyte-stimulating hormone receptor (MSHR), melanin-activating peptide receptor, or melanotropin receptor, is a G protein–coupled receptor that binds to a class of pituitary peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH) and the different forms of melanocyte-stimulating hormone (MSH). It is coupled to Gαs and upregulates levels of cAMP by activating adenylyl cyclase in cells expressing this receptor. It is normally expressed in skin and melanocytes, and to a lesser degree in periaqueductal gray matter, astrocytes and leukocytes. In skin cancer, MC1R is highly expressed in melanomas but not carcinomas.
Arterial calcification due to deficiency of CD73 (ACDC) is a rare genetic disorder that causes calcium buildup in the arteries and joints of the hands and feet, and other areas below the waist. Although patients exhibiting these symptoms have been identified as early as 1914, this disorder had not been studied extensively until recently. The identification of the specific ACDC gene and mutations occurred in 2011. ACDC is caused by a mutation in the NT5E gene, which prevents calcium-removing agents from functioning,. Patients with this mutation experience chronic pain, difficulty moving, and increased risk of cardiovascular problems. In experiments at the molecular level, treatment with adenosine or a phosphatase inhibitor reversed and prevented calcification, suggesting they could be used as possible treatment methods. There is currently no cure for ACDC, and patients have limited treatment options which focus primarily on removal of blood calcium and improving mobility.
Biobank ethics refers to the ethics pertaining to all aspects of biobanks. The issues examined in the field of biobank ethics are special cases of clinical research ethics.
Interferon lambda 3 encodes the IFNL3 protein. IFNL3 was formerly named IL28B, but the Human Genome Organization Gene Nomenclature Committee renamed this gene in 2013 while assigning a name to the then newly discovered IFNL4 gene. Together with IFNL1 and IFNL2, these genes lie in a cluster on chromosomal region 19q13. IFNL3 shares ~96% amino-acid identity with IFNL2, ~80% identity with IFNL1 and ~30% identity with IFNL4.
Philip Awadalla is a professor of medical and population genetics at the Ontario Institute for Cancer Research, and the Department of Molecular Genetics, Faculty of Medicine, University of Toronto. He is the National Scientific Director of the Canadian Partnership for Tomorrow's Health (CanPath), formerly the Canadian Partnership for Tomorrow Project (CPTP), and executive director of the Ontario Health Study. He is also the Executive Scientific Director of the Genome Canada Genome Technology Platform, the Canadian Data Integration Centre. Professor Awadalla was the Executive Scientific Director of the CARTaGENE biobank, a regional cohort member of the CPTP, from 2009 to 2015, and is currently a scientific advisor for this and other scientific and industry platforms. At the OICR, he is Director of Computational Biology.
Ets variant 5 (ETV5) is a transcription factor that in humans is encoded by the ETV5 gene. It is generated in Sertoli cells, which are found in the testes and play a crucial role in spermatogenesis. Its ortholog has been linked to both obesity and bipolar disorder.
Calcium channel, voltage-dependent, alpha 2/delta subunit 3 is a protein that in humans is encoded by the CACNA2D3 gene on chromosome 3 .
Health among the Amish is characterized by higher incidences of particular genetic disorders, especially among the Old Order Amish. These disorders include dwarfism, Angelman syndrome, and various metabolic disorders, such as Tay-Sachs disease, as well as an unusual distribution of blood types.
Jeffrey S. Mogil, FCAHS, FRSC is a Canadian neuroscientist and the E.P. Taylor Professor of Pain Studies and Distinguished James McGill Professor at McGill University. He is known for his work in the genetics of pain, for being among the first scientists to demonstrate sex differences in pain perception, and for identifying previously unknown factors and confounds that affect the integrity of contemporary pain research. He has an h-index of 100.
Luda Diatchenko is an academic and researcher at McGill University in Quebec, Canada, with a research focus on pain in humans. She is the Canada Excellence Research Chair (CERC) in Human Pain Genetics Laureate and the Fellow of the Royal Society of Canada.